Cerus Co. (NASDAQ:CERS) shares traded down 0.9% on Thursday . The stock traded as low as $4.31 and last traded at $4.39. 1,046,332 shares changed hands during mid-day trading, a decline of 50% from the average session volume of 2,077,308 shares. The stock had previously closed at $4.43.

Several research analysts have recently weighed in on the company. ValuEngine raised Cerus from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. Zacks Investment Research lowered Cerus from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. BTIG Research reissued a “neutral” rating on shares of Cerus in a research report on Friday, December 8th. BidaskClub raised Cerus from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $5.00 price objective on shares of Cerus in a research report on Friday, January 5th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $5.83.

The company has a current ratio of 3.71, a quick ratio of 3.11 and a debt-to-equity ratio of 0.80. The company has a market cap of $504.97, a P/E ratio of -7.41 and a beta of 1.93.

Cerus (NASDAQ:CERS) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. The company had revenue of $10.80 million during the quarter, compared to the consensus estimate of $11.95 million. Cerus had a negative return on equity of 142.18% and a negative net margin of 159.35%. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the business posted ($0.14) EPS. analysts anticipate that Cerus Co. will post -0.58 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of CERS. Ark Investment Management LLC grew its stake in shares of Cerus by 126.5% in the 2nd quarter. Ark Investment Management LLC now owns 1,680,925 shares of the biotechnology company’s stock valued at $4,219,000 after buying an additional 938,647 shares during the period. Elk Creek Partners LLC grew its stake in shares of Cerus by 6.8% in the 3rd quarter. Elk Creek Partners LLC now owns 6,128,026 shares of the biotechnology company’s stock valued at $16,730,000 after buying an additional 388,741 shares during the period. First Midwest Bank Trust Division grew its stake in shares of Cerus by 50.3% in the 3rd quarter. First Midwest Bank Trust Division now owns 1,078,277 shares of the biotechnology company’s stock valued at $2,944,000 after buying an additional 360,785 shares during the period. Vanguard Group Inc. grew its stake in shares of Cerus by 3.9% in the 2nd quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock valued at $12,281,000 after buying an additional 184,076 shares during the period. Finally, Premier Asset Management LLC acquired a new stake in shares of Cerus in the 3rd quarter valued at about $348,000. Institutional investors own 55.77% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Cerus (CERS) Stock Price Down 0.9%” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/02/01/cerus-cers-stock-price-down-0-9.html.

About Cerus

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.